Bristol/Otsuka To Submit Abilify Long-Term Efficacy sNDA As Phase IV
This article was originally published in Pharmaceutical Approvals Monthly
Otsuka/Bristol-Myers Squibb are required to submit an NDA supplement before the end of 2002 on long-term efficacy of its schizophrenia drug Abilify
You may also be interested in...
Bristol-Myers Squibb and Otsuka will take their second stab at an Abilify indication for bipolar mania via an sNDA submission before the end of 2003.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011